Screener
Eligibility screening
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab
9 US sites in CA, FL, OH, PA +2
Before we begin
Who are you filling this out for?
Your answer affects how the questions are phrased.